Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan.

MLA

Chen, Kuei-An, et al. “Cost-Effectiveness of Ivosidenib versus Chemotherapy for Previously Treated IDH1-Mutant Advanced Intrahepatic Cholangiocarcinoma in Taiwan.” BMC Cancer, vol. 24, no. 1, May 2024, p. 622. EBSCOhost, https://doi.org/10.1186/s12885-024-12362-y.

APA

Chen, K.-A., Huang, W.-M., Chen, E. Y.-T., Ho, P.-K., Chueh, C.-H., Wen, Y.-W., Chen, M.-H., Chiang, N.-J., & Tsai, Y.-W. (2024). Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan. BMC Cancer, 24(1), 622. https://doi.org/10.1186/s12885-024-12362-y

Chicago

Chen, Kuei-An, Wei-Ming Huang, Eric Yi-Ting Chen, Pei-Kuan Ho, Chen-Han Chueh, Yu-Wen Wen, Ming-Huang Chen, Nai-Jung Chiang, and Yi-Wen Tsai. 2024. “Cost-Effectiveness of Ivosidenib versus Chemotherapy for Previously Treated IDH1-Mutant Advanced Intrahepatic Cholangiocarcinoma in Taiwan.” BMC Cancer 24 (1): 622. doi:10.1186/s12885-024-12362-y.